- AU$23.65m
- AU$22.58m
- AU$19.70m
- 63
- 42
- 60
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.44 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.48 | ||
| Price to Tang. Book | 3.19 | ||
| Price to Free Cashflow | 57.04 | ||
| Price to Sales | 1.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.54% | ||
| Return on Equity | -26.3% | ||
| Operating Margin | -19.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 7.87 | 10.93 | 13.39 | 17.16 | 19.7 | 24.4 | 30.9 | 26.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +500 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IMEXHS Limited is an Australia-based provider of medical imaging software and radiology services in 18 countries, including Colombia, the United States and Australia. The Company develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The Company's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.
Directors
- Douglas Flynn NEC
- German Arango CEO
- Reena Minhas CFO
- German Fumis GMG
- Jorge Marin OTH
- Andres Vanegas OTH
- Alejandro Varettoni OTH
- Douglas Lingard NED
- John Mactaggart NED
- Carlos Jaime Palacio NED
- Damian Banks NID (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 3rd, 2001
- Public Since
- December 14th, 2005
- No. of Shareholders
- 921
- No. of Employees
- 400
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 42,607,692
- Address
- 122 O'Riordan Street, MASCOT, 2020
- Web
- http://omnimarkettide.com/
- Phone
- +61 290300040
- Auditors
- Nexia Sydney Audit Pty Limited
Upcoming Events for IME
Half Year 2024 ImExHS Ltd Earnings Release
Similar to IME
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the ImExHS share price?
As of Today at 19:11 UTC, shares in ImExHS are trading at AU$0.56. This share price information is delayed by 15 minutes.
How has the ImExHS share price performed this year?
Shares in ImExHS last closed at AU$0.56 and the price had moved by -5.93% over the past 365 days. In terms of relative price strength the ImExHS share price has underperformed the ASX All Ordinaries Index by -12.38% over the past year.
What are the analyst and broker recommendations for ImExHS?
The overall consensus recommendation for ImExHS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ImExHS dividend yield?
ImExHS does not currently pay a dividend.
Does ImExHS pay a dividend?
ImExHS does not currently pay a dividend.
When does ImExHS next pay dividends?
ImExHS does not currently pay a dividend.
How do I buy ImExHS shares?
To buy shares in ImExHS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ImExHS?
As of the previous close price of AU$0.56, shares in ImExHS had a market capitalisation of AU$23.65m.
Where are ImExHS shares listed?
Here are the trading details for ImExHS:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IME
What kind of share is ImExHS?
Based on an overall assessment of its quality, value and momentum ImExHS is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ImExHS share price forecast for 2024?
The analyst consensus target price for shares in ImExHS is AU$1.50. That is 170.27% above the last closing price of AU$0.56.
Analysts covering ImExHS currently have a consensus Earnings Per Share (EPS) forecast of AU$0.02 for the next financial year.
What is the trend in the ImExHS share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImExHS. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -17.35%.
As of the last closing price of AU$0.56, shares in ImExHS were trading -3.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ImExHS PE Ratio?
The ImExHS PE ratio based on its reported earnings over the past 12 months is 11.44. The shares last closed at AU$0.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ImExHS?
ImExHS' management team is headed by:
- Douglas Flynn - NEC
- German Arango - CEO
- Reena Minhas - CFO
- German Fumis - GMG
- Jorge Marin - OTH
- Andres Vanegas - OTH
- Alejandro Varettoni - OTH
- Douglas Lingard - NED
- John Mactaggart - NED
- Carlos Jaime Palacio - NED
- Damian Banks - NID